Mayo Clinic Laboratories now offers a comprehensive addiction rehabilitation monitoring profile, an innovative assay that employs a combination of technologies to test urine for the most commonly used substances. In this test specific episode of the "Answers From the Lab" podcast, Loralie Langman, Ph.D., and Paul Jannetto, Ph.D., discuss the test’s utility to help guide and monitor treatment.

“Urine drug testing has been referred to as the technology of addiction treatment,” Dr. Jannetto says. “It’s not meant to be punitive, but rather as a tool to support recovery and provide motivation or reinforcement for abstinence.”

Developed for clinicians who manage complex patients struggling with substance use disorders to common substances such as opioids, marijuana, alcohol, and nicotine, the addiction monitoring profile offers improved specificity and includes adulterant testing and enhanced reports. Listen to learn more about how our testing enables accurate answers and simplified results to clarify patients’ substance use.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ADMPU | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

Useful information

• Assessing patients at-risk for substance use disorders.
• Detecting drug use involving stimulants, barbiturates, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, alcohol, and nicotine.
• This test is not intended for use in employment-related testing.

Specimen requirements

Specimen Type: Urine Container, 60 mL (T313)

Specimen Volume: 30 mL

Container/Tube: Plastic urine container

Collection Instructions:

• Collect a random urine specimen.
• Submit 30 mL in 1 plastic bottle.
• No preservative.

Additional Information:

• No specimen substitutions.
• Submitting less than 30 mL may compromise the ability to perform all necessary testing.
• STATS are not accepted for this procedure.

Performance information

Analytic time: 2 to 5 days 

Days performed: Varies

The latest

Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP

April 8, 2025

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.

January 21, 2025

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

View MoreView Less